NITROPRESS

Post-LOE

sodium nitroprusside

Sagent Pharmaceuticals

ANDAINJECTIONINJECTABLE

Approved

Aug 1988

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

NITROPRESS (sodium nitroprusside) by Sagent Pharmaceuticals is clinical pharmacology the principal pharmacological action of sodium nitroprusside is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Approved for acute congestive heart failure. First approved in 1988.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The principal pharmacological action of sodium nitroprusside is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on…

Worked on NITROPRESS at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NITROPRESS

Mechanism of Action

Indications (1)

Clinical Trials (1)